Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Analysts

Shares of Galapagos NV (NASDAQ:GLPG) have received a consensus recommendation of “Reduce” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $30.75.

A number of analysts have recently weighed in on the company. TD Cowen cut Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday, November 20th. Finally, Royal Bank of Canada cut their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st.

Galapagos Trading Down 0.6 %

Shares of NASDAQ:GLPG opened at $23.76 on Monday. Galapagos has a 12-month low of $23.53 and a 12-month high of $40.34. The business’s fifty day simple moving average is $26.93 and its 200-day simple moving average is $27.49.

Institutional Investors Weigh In On Galapagos

A number of institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC lifted its stake in Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 446 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Galapagos by 140.7% during the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Galapagos by 63.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,510 shares during the period. Rhumbline Advisers grew its holdings in shares of Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 814 shares in the last quarter. Finally, Signaturefd LLC increased its stake in Galapagos by 65.6% during the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company’s stock worth $185,000 after buying an additional 2,541 shares during the period. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.